Grace Lai‐Hung Wong, Lilian Yan Liang, Raymond Kwok, Aric Josun Hui, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong – 25 January 2019 – We previously demonstrated the possible noninferiority of a screening strategy for varices guided by liver and spleen stiffness measurement (LSSM) compared to universal endoscopic screening in detecting clinically significant varices in patients with cirrhosis. We now report the long‐term outcome of the patients recruited in this trial for incident variceal bleeding and other hepatic events.

Heidi Yeh, Korkut Uygun – 25 January 2019

Hiam Chemaitelly, Sarwat Mahmud, Silva P. Kouyoumjian, Zaina Al‐Kanaani, Joumana G. Hermez, Laith J. Abu‐Raddad – 23 January 2019 – Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study assessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program efficiency of testing strategies. A standardized and systematically assembled database of 2,542 HCV antibody prevalence studies on 49 million individuals was analyzed.

Mohammad Bilal Siddiqui, Tamoore Arshad, Samarth Patel, Emily Lee, Somaya Albhaisi, Arun J. Sanyal, R. Todd Stravitz, Carolyn Driscoll, Richard K. Sterling, Trevor Reichman, Chandra Bhati, Mohammad Shadab Siddiqui – 23 January 2019 – Cardiovascular disease (CVD) is an important cause of morbidity and mortality after liver transplantation (LT). Although LT is associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact of these subparticles on CVD‐related events is unknown.

Xu Ye, Cunyan Li, Xuyu Zu, Minglin Lin, Qiang Liu, Jianghua Liu, Guoguo Xu, Zhiyong Chen, Yongliang Xu, Long Liu, Diteng Luo, Zhe Cao, Guiyuan Shi, Zirui Feng, Hongyu Deng, Qianjin Liao, Chuan Cai, Duan‐Fang Liao, Jing Wang, Junfei Jin, Deliang Cao – 23 January 2019 – Aldo‐keto reductase family 1 member B10 (AKR1B10) is a secretory protein overexpressed in hepatocellular carcinoma (HCC). We aimed to evaluate AKR1B10 as a serum marker for detection of HCC.

Daniel S. Pratt – 23 January 2019

Akira Hiramatsu, Hiroshi Aikata, Shinsuke Uchikawa, Kazuki Ohya, Kenichiro Kodama, Yuno Nishida, Kana Daijo, Mitsutaka Osawa, Yuji Teraoka, Fumi Honda, Yuki Inagaki, Kei Morio, Reona Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Michio Imamura, Junko Tanaka, Kazuaki Chayama – 22 January 2019 – Although the effect of levocarnitine (L‐carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its effect on sarcopenia remains to be elucidated.

Christian Jansen, Anna Schröder, Robert Schueler, Jennifer Lehmann, Michael Praktiknjo, Frank E. Uschner, Robert Schierwagen, Daniel Thomas, Sofia Monteiro, Georg Nickenig, Christian P. Strassburg, Carsten Meyer, Vicente Arroyo, Christoph Hammerstingl, Jonel Trebicka – 22 January 2019 – Acute deterioration of liver cirrhosis (e.g., infections, acute‐on‐chronic liver failure [ACLF]) requires an increase in cardiac contractility. The insufficiency to respond to these situations could be deleterious.

John‐Paul Berauer, Anya I. Mezina, David T. Okou, Aniko Sabo, Donna M. Muzny, Richard A. Gibbs, Madhuri R. Hegde, Pankaj Chopra, David J. Cutler, David H. Perlmutter, Laura N. Bull, Richard J. Thompson, Kathleen M. Loomes, Nancy B. Spinner, Ramakrishnan Rajagopalan, Stephen L. Guthery, Barry Moore, Mark Yandell, Sanjiv Harpavat, John C. Magee, Binita M. Kamath, Jean P. Molleston, Jorge A. Bezerra, Karen F. Murray, Estella M. Alonso, Philip Rosenthal, Robert H. Squires, Kasper S. Wang, Milton J. Finegold, Pierre Russo, Averell H. Sherker, Ronald J. Sokol, Saul J.

Zhipeng Yan, Daitze Wu, Hui Hu, Jing Zeng, Xin Yu, Zhiheng Xu, Zheng Zhou, Xue Zhou, Guang Yang, John A.T. Young, Lu Gao – 21 January 2019 – Hepatitis B e antigen (HBeAg) is an important immunomodulator for promoting host immune tolerance during chronic hepatitis B (CHB) infection. In patients with CHB, HBeAg loss and seroconversion represent partial immune control of CHB infection and are regarded as valuable endpoints. However, the current approved treatments have only a limited efficacy in achieving HBeAg seroconversion in HBeAg‐positive patients.